Skip to main content
SpringerLink
Log in

Zytokin-Inhibitoren in der pädiatrischen Rheumatologie

  • Chapter
  • First Online:
Pädiatrische Rheumatologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1368 Accesses

Zusammenfassung

Zytokine sind die Botenstoffe, die das Ausmaß einer entzündlichen Reaktion auf pathogene Keime und einer Autoimmunreaktion regulieren; sie können pro- oder antiinflammatorisch wirken. In den letzten 20 Jahren sind zahlreiche Medikamente zugelassen worden, die die Wirkung von Zytokinen modulieren und damit antientzündlich wirksam sind. In dem folgenden Kapitel werden Antagonisten von TNF-α, IL-1, IL-6, IL-17 sowie IL-12 und IL-23 in ihrer Wirkungsweise und praktischen Anwendung vorgestellt. Biologika sind Substanzen, die von genetisch veränderten Organismen in einem biologischen Prozess – im Unterschied zu einem chemischen Prozess – hergestellt werden. Dazu gehören gegen Zytokine gerichtete monoklonale Antikörper (MAK) und Fusionsproteine (FP).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 229.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C (2018) Interleukin 12/interleukin 23 pathway: biological basis and therapeutic effect in patients with Crohn’s disease. World J Gastroenterol 24:4093–4103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Benson JM, Peritt D, Scallon BJ, Heavner GA et al (2011) MAbs. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3:535–545

    Article  PubMed  PubMed Central  Google Scholar 

  • Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S et al (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 69(4):854–862

    Article  CAS  PubMed  Google Scholar 

  • Boyman O, Comte D, Spertini F (2014) Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 10(10):612–627

    Article  CAS  PubMed  Google Scholar 

  • Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, for the Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. pii: annrheumdis-2014-205351. Ann Rheum Dis 74(6):1110–1117

    Google Scholar 

  • Brunner HI, Rider LG, Kingsbury DJ, Co D, Schneider R, Goldmuntz E et al (2018) Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol Online J 16(1):45

    Article  PubMed  PubMed Central  Google Scholar 

  • Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S et al (2015) A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res 67(11):1503–1512

    Article  CAS  Google Scholar 

  • Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840–847

    Article  CAS  PubMed  Google Scholar 

  • Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–3150

    Article  CAS  PubMed  Google Scholar 

  • De Benedetti F, Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 25:203–207

    PubMed  Google Scholar 

  • De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385–2395

    Article  CAS  PubMed  Google Scholar 

  • Dinarello CA, Joosten LA (2016) Inflammation in rheumatology in 2015: new tools to tackle inflammatory arthritis. Nat Rev Rheumatol 12(2):78–80

    Article  CAS  PubMed  Google Scholar 

  • Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193

    Article  CAS  PubMed  Google Scholar 

  • Ehmann LM, Tillack-Schreiber C, Brand S, Wollenberg A (2012) Malignant melanoma during ustekinumab therapy of Crohn’s disease. Inflamm Bowel Dis 18(1):E199–E200

    Article  PubMed  Google Scholar 

  • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105–1110

    Article  CAS  PubMed  Google Scholar 

  • Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR (2017) Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum 69:277–290

    Article  CAS  Google Scholar 

  • Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C et al (2015) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum 67:1424–1437

    Article  CAS  Google Scholar 

  • Gosh S, Gensler SG, Yang Z et al (2019) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Drug Saf 42:751–768

    Article  CAS  Google Scholar 

  • Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P (2011) Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 147(10):1197–1202

    Article  PubMed  Google Scholar 

  • Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C et al (2019) Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 49(1):43–55

    Article  CAS  PubMed  Google Scholar 

  • Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N et al (2012) Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 14(5):R230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kummerle-Deschner JB, Tenbrock K et al (2015) Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheum 67(8):2240–2249

    Article  CAS  Google Scholar 

  • Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A (2016) Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 18(1):272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP (2017) Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 19(1):256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iida Y, Wakiguchi H, Okazaki F, Nakamura T, Yasudo H, Kubo M et al (2019) Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene. Clin Rheumatol 38(3):943–948

    Article  PubMed  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2012) Vorbericht A10-01: Biologika – Zweitlinientherapie bei rheumatoider Arthritis

    Google Scholar 

  • Ito H, Takazoe M, Fukuda Y et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126:989–996

    Article  CAS  PubMed  Google Scholar 

  • Jager W de, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66(5):589–598

    Google Scholar 

  • Kostner K, Prelog M, Almanzar G, Feq H, Haas JP, Hugle B (2018) Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology 57:936–938

    Article  PubMed  Google Scholar 

  • Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S et al (2003) Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 71(5):396–398

    Article  PubMed  Google Scholar 

  • Landells I, Marano C, Hsu MC et al (2015) Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Dermatol 73:594–603

    Article  CAS  Google Scholar 

  • Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23(8):943–947

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lehman TJ (2008) Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 372(9636):348–350

    Article  PubMed  Google Scholar 

  • Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769

    Article  CAS  PubMed  Google Scholar 

  • Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820

    Article  CAS  PubMed  Google Scholar 

  • Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 17:57

    Article  PubMed  PubMed Central  Google Scholar 

  • McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S (2015) FUTURE 2 Study Group (2015) Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137–1146

    Google Scholar 

  • Mease PJ, van der Heijde D, Ritchlin CT et al (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatric arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab-)controlled period oft he pphase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79–87

    Article  CAS  PubMed  Google Scholar 

  • Molinelli E, Campanati A, Ganzetti G, Offidani A (2016) Biologic therapy in immune mediated inflammatory disease: basic science and clinical concepts. Curr Drug Saf 11(1):35–43

    Article  CAS  PubMed  Google Scholar 

  • Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348–354

    Article  CAS  PubMed  Google Scholar 

  • Nash P, Kirkham B, Okada M et al (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period or the SPIRIT-P2 phase 3 trial. Lancet 389(10086):2317–2327

    Article  CAS  PubMed  Google Scholar 

  • Niehues T (2018) Therapeutic monoclonal antibodies as immunomodulators and anti-cancer agents: development, evidence of efficacy, mechanisms of actions, adverse effects. In: Imbach P (Hrsg) Antibody therapy – substitution – immunomodulation – monoclonal immunotherapy. Springer International Publishing, Cham, S 291–341

    Chapter  Google Scholar 

  • Niehues T, Ozgur TT (2019) The efficacy and evidence-based use of biologics in children and adolescents: using monoclonal antibodies and fusion proteins as treatments. Dtsch Arztebl Int 116(42):703–710

    PubMed  PubMed Central  Google Scholar 

  • Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555

    Article  CAS  PubMed  Google Scholar 

  • Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632

    Article  CAS  PubMed  Google Scholar 

  • Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR (2008) Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 58(3):875–887

    Article  PubMed  PubMed Central  Google Scholar 

  • Noguera-Julian A, Calzada-HernAndez J, Brinkmann F, Basu Roy R, Bilogortseva O, Buettcher M et al (2019) Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study. Clin Infect Dis 71:2561–2569

    Article  CAS  Google Scholar 

  • Oommen PT (2020) Recommendation for action according to the S2k guideline Treatment of juvenile idiopathic arthritis. Monatsschr Kinderheilkd 168:947–949

    Article  Google Scholar 

  • Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP et al (2011a) Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis 70(2):337–340

    Google Scholar 

  • Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M et al (2011b) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306(21):2340–2347

    Article  CAS  PubMed  Google Scholar 

  • Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241–251

    Article  CAS  PubMed  Google Scholar 

  • Paller AS, Seyger MMB, Alejandro Magarinos G et al (2020) Efficacy and safety of Ixekizumab in a phase III, randomized, double-blind, placebo-controlled Study in paediatric patients with moderate-to-severe Plaque Psoriasis (IXORA-PEDS). Br J Dermatol. https://doi.org/10.1111/bjd.19147

  • Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED (2011) Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 23(12):1150–1156

    Article  CAS  PubMed  Google Scholar 

  • Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2019) Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. J Rheumatol 46:1117–1126

    Article  CAS  PubMed  Google Scholar 

  • Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C et al (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–754

    Article  CAS  PubMed  Google Scholar 

  • Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S et al (2017) Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 376(17):1637–1646

    Article  CAS  PubMed  Google Scholar 

  • Ritchlin C, Rahman P, Kavanaugh A et al (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990–999

    Article  CAS  PubMed  Google Scholar 

  • Robert M, Miossec P (2019) IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Front Med 5:364

    Article  Google Scholar 

  • Rosser EC, Lom H, Bending D, Duurland CL, Bajaj-Elliott M, Wedderburn LR (2019) Innate lymphoid cells and T cells contribute to the interleukin-17A signature detected in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 71(3):460–467

    Article  CAS  Google Scholar 

  • Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebocontrolled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–3106

    Article  CAS  PubMed  Google Scholar 

  • Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R et al (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64(2):557–567

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Rutgeerts P, Gasink C et al (2018) Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther 48:65–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64(7):2375–2386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63(4):612–618

    Article  CAS  Google Scholar 

  • Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18–23

    Article  CAS  PubMed  Google Scholar 

  • Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596

    Article  CAS  PubMed  Google Scholar 

  • Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377(4):317–328

    Article  CAS  PubMed  Google Scholar 

  • Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E et al (2018) Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 20(1):285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M et al (2011) Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 70(9):1605–1612

    Article  CAS  PubMed  Google Scholar 

  • Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS et al (2012) Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 64(6):2012–2021

    Article  PubMed  Google Scholar 

  • Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20(2):259–262

    CAS  PubMed  Google Scholar 

  • Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818–825. https://doi.org/10.1002/art.20944

    Article  CAS  PubMed  Google Scholar 

  • Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998–1006. https://doi.org/10.1016/S0140-6736(08)60454-7

    Article  CAS  PubMed  Google Scholar 

  • Young L, Czarnecki D (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53(1):57–60

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Helios Kliniken Krefeld, Zentrum für Kinder- und Jugendmedizin, Krefeld, Deutschland

    Tim Niehues

  2. Zentrum Allgemeine Pädiatrie und Neonatologie, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Deutschland

    Gerd Horneff

  3. Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Immunologie, Technischen Universität Dresden, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland

    Catharina Schütz

  4. Leiter des Bereichs Pädiatrische Rheumatologie, Universitätsklinikum Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie, Düsseldorf, Deutschland

    Prasad Thomas Oommen

Authors
  1. Tim Niehues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerd Horneff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catharina Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prasad Thomas Oommen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim Niehues .

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  2. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Günther Dannecker

  3. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Niehues, T., Horneff, G., Schütz, C., Oommen, P.T. (2022). Zytokin-Inhibitoren in der pädiatrischen Rheumatologie. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60410-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-60410-6_18

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-60409-0

  • Online ISBN: 978-3-662-60410-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation